Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from GlaxoSmithKline ( (GB:GSK) ).
GSK has continued its share buyback programme, repurchasing 505,000 ordinary shares on 10 March 2026 through BNP Paribas at a volume‑weighted average price of 2,066.69 pence, with the stock to be held in treasury. This latest tranche lifts total repurchases since 17 February to 8,177,000 shares, taking treasury holdings to 248,068,094 shares, or 6.10% of voting rights, and leaves 4,068,100,728 shares in issue, information that helps investors track ownership thresholds under U.K. disclosure rules.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £19.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Neutral.
The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
GSK plc is a global biopharmaceutical company focused on developing, manufacturing and marketing prescription medicines, vaccines and consumer healthcare products. The group targets major therapeutic areas including infectious diseases, respiratory conditions and immunology, with a significant presence in U.K. and international capital markets.
Average Trading Volume: 9,067,371
Technical Sentiment Signal: Buy
Current Market Cap: £82.68B
See more data about GSK stock on TipRanks’ Stock Analysis page.